Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 1/2 4

Status

Recruiting 8Completed 6Active not recruiting 4Unknown 3Terminated 2Withdrawn 1

Sponsor Class

INDUSTRY 6OTHER_GOV 2

Study Type

Interventional 8

Sponsor

Cancer Type

Gastrointestinal 8Other hematologic neoplasm 1Lymphoid 1

Conditions

Colorectal Neoplasms 4Stomach Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Oxaliplatin 197Bevacizumab 162Fluorouracil 155Capecitabine 137Gemcitabine 133Leucovorin 112pembrolizumab 99Cisplatin 93Drug Therapy 89Irinotecan 81Radiotherapy 73sintilimab 70durvalumab 65130-nm albumin-bound paclitaxel 65Paclitaxel 64Specimen Handling 62Cetuximab 61lenvatinib 59tislelizumab 58Nivolumab 55Magnetic Resonance Spectroscopy 55Folfox protocol 55Blood Specimen Collection 52atezolizumab 48Biopsy 46Surgical Procedures, Operative 40Taxes 38Albumin-Bound Paclitaxel 38Immune Checkpoint Inhibitors 37HMPL-013 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Recruiting × Levoleucovorin × Gastrointestinal × Clear all
NCT06662786 2026-06-05

OrigAMI-2

Janssen Research & Development, LLC

Phase 3 Recruiting
1,000 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06750094 2026-06-05

OrigAMI-3

Janssen Research & Development, LLC

Phase 3 Recruiting
700 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT05253651 2026-06-04

MOUNTAINEER-03

Seagen Inc.

Phase 3 Recruiting
400 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06469944 2026-05-26

MK-3475-06C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
160 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT06780111 2026-03-31

MK-3475-06E

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
298 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06428409 2026-01-22

MK-9999-02A

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
220 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Colorectal Neoplasms

NCT06793917 2025-07-20

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Fujian Cancer Hospital

Phase 3 Recruiting
269 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05319639 2025-02-27

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

Fujian Cancer Hospital

Phase 1/2 Recruiting
51 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡